ArticleInternational journal of biological sciences2016
Lyophilized Powder of Catalpol and Puerarin Protects Neurovascular Unit from Stroke.
Article in International journal of biological sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Research Hotspots and Frontiers of Ischemic Stroke and Traditional Chinese Medicine: A Knowledge Mapping and Text Mining Analysis.Current neuropharmacology · 2026Article
- An ultrasonic degraded polysaccharide extracted from Pueraria lobata ameliorate ischemic brain injury in mice by regulating the gut microbiota and LPS-TLR4 pathway.Ultrasonics sonochemistry · 2025Article
- Article
- Combined administration of catalpol, puerarin, gastrodin, and borneol modulates the Tlr4/Myd88/NF-κB signaling pathway and alleviates microglia inflammation in Alzheimer's disease.Frontiers in pharmacology · 2024Article
- Protective effects of catalpol on cardio-cerebrovascular diseases: A comprehensive review.Journal of pharmaceutical analysis · 2023Review
- Phytochemicals in the treatment of inflammation-associated diseases: the journey from preclinical trials to clinical practice.Frontiers in pharmacology · 2023Review
- Exploring the Therapeutic Potential of Phytochemicals in Alzheimer's Disease: Focus on Polyphenols and Monoterpenes.Frontiers in pharmacology · 2022Review
- Pueratin improves diminished ovarian reserve by inhibiting apoptosis.Experimental and therapeutic medicine · 2021Article
- A novel PGAM5 inhibitor LFHP-1c protects blood-brain barrier integrity in ischemic stroke.Acta pharmaceutica Sinica. B · 2021Article
- Network Pharmacology-Based Prediction of Catalpol and Mechanisms against Stroke.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Effects of Puerarin on the Prevention and Treatment of Cardiovascular Diseases.Frontiers in pharmacology · 2021Review
- A Review of Edible Jujube, theFrontiers in pharmacology · 2020Review
- Catalpol induces cell activity to promote axonal regeneration via the PI3K/AKT/mTOR pathwayAnnals of translational medicine · 2019Article
- Catalpol may improve axonal growth via regulating miR-124 regulated PI3K/AKT/mTOR pathway in neurons after ischemia.Annals of translational medicine · 2019Article
- Antitumor activity of integrin αTranslational cancer research · 2019Article
- Structural and functional damage to the hippocampal neurovascular unit in diabetes-related depression.Neural regeneration research · 2019Article
- Cryptotanshinone Attenuates Oxygen-Glucose Deprivation/ Recovery-Induced Injury in anFrontiers in neurology · 2019Article
- Troxerutin and Cerebroprotein Hydrolysate Injection Protects Neurovascular Units from Oxygen-Glucose Deprivation and Reoxygenation-Induced InjuryEvidence-based complementary and alternative medicine : eCAM · 2018Article
- Effects of puerarin combined with conventional therapy on ischemic stroke.Experimental and therapeutic medicine · 2017Article
- Lyophilized Powder of Catalpol and Puerarin Protected Cerebral Vessels from Ischemia by Its Anti-apoptosis on Endothelial Cells.International journal of biological sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hunting for an effective medicine for brain stroke has been a medical task in neuroscience for decades. The present research showed that the lyophilized Powder of Catalpol and Puerarin (C-P) in all the tested doses (65.4 mg/kg, 32.7 mg/kg, 16.4 mg/kg) significantly reduced the neurological deficiency, infarct volume and apoptotic cells in ischemic/reperfusion (I/R) rats. It also promoted astrocyte processes and prolonged neuron axons in infarct area. Further, it decreased MDA, NO, NF-κB/p65, TNF-α, IL-1β and IL-6 and enhanced the EPOR and GAF-43. 65.4 mg/kg and 32.7 mg/kg C-P could up-regulated EPO and VEGF significantly. In vitro, 49 μg/mL and 24.5 μg/mL C-P decreased the leakage of sodium fluorescein and increased the activity of γ-GTP. Additionally, it increased SOD and decreased MDA, NO, and LDH and decreased NF-κB/p65, TNF-α, IL-1β and IL-6 and unregulated EPO, EPOR, VEGF, and GAP-43. Only the dose of 49 μg/mL increased TEER and Claudin-5 and turned the typically damaged morphologies of neurons, astrocytes and endothelium into a favorable trend. These data imply that C-P improved the recovery of neurological deficiency in motor, sense, balance and reflex, and protected the whole NVU by anti-oxidative stress, anti-inflammation and up-regulating some protective factors. This research provides a candidate medicine for brain stroke and, at the same time, a pattern for drug study targeting NVU in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.